Full View

FDA approval summary: Pembrolizumab for the treatment of recurrent or metastatic head and neck squamous cell carcinoma with disease progression on or after …

E Larkins, GM Blumenthal, W Yuan, K He… - The …, 2017 - academic.oup.com
Abstract On August 5, 2016, the US Food and Drug Administration granted accelerated
approval to pembrolizumab (KEYTRUDA injection, Merck Sharp & Dohme Corp., Kenilworth …
被引用次数：202 相关文章

FDA Approval Summary: Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Disease Progression on or After …

E Larkins, GM Blumenthal, W Yuan, K He… - …, 2017 - search.ebscohost.com
Abstract On August 5, 2016, the US Food and Drug Administration granted accelerated
approval to pembrolizumab (KEYTRUDA injection, Merck Sharp & Dohme Corp …

FDA Approval Summary: Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Disease Progression on or After …

E Larkins, GM Blumenthal, W Yuan, K He, R Sridhara… - The Oncologist, 2017 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: p> On August 5, 2016, the US Food and Drug
Administration granted accelerated approval to pembrolizumab (KEYTRUDA injection …

FDA Approval Summary: Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Disease Progression on or After …

E Larkins, GM Blumenthal, W Yuan, K He… - The …, 2017 - pubmed.ncbi.nlm.nih.gov
On August 5, 2016, the US Food and Drug Administration granted accelerated approval to
pembrolizumab (KEYTRUDA injection, Merck Sharp & Dohme Corp., Kenilworth, NJ) for …
[HTML] nih.gov

[HTML][HTML] FDA Approval Summary: Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Disease Progression …

E Larkins, GM Blumenthal, W Yuan, K He… - The …, 2017 - ncbi.nlm.nih.gov
ABSTRACT On August 5, 2016, the US Food and Drug Administration granted accelerated
approval to pembrolizumab (KEYTRUDA injection, Merck Sharp & Dohme Corp., Kenilworth …
[PDF] wiley.com

[PDF][PDF] FDA Approval Summary: Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Disease Progression on …

E Larkins, GM Blumenthal, W Yuan, K He… - The …, 2017 - Wiley Online Library
Abstract On August 5, 2016, the US Food and Drug Administration granted accelerated
approval to pembrolizumab (KEYTRUDA injection, Merck Sharp & Dohme Corp., Kenilworth …

FDA Approval Summary: Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Disease Progression on or After …

E Larkins, GM Blumenthal, W Yuan, K He… - The …, 2017 - europepmc.org
Abstract On August 5, 2016, the US Food and Drug Administration granted accelerated
approval to pembrolizumab (KEYTRUDA injection, Merck Sharp & Dohme Corp., Kenilworth …